Skip to main content
. 2021 Sep 25;10(19):e021685. doi: 10.1161/JAHA.121.021685

Figure 3. Rilonacept mechanism of action.

Figure 3

Rilonacept ultrastructure with 3 main components: the ligand binding‐domain of the human IL‐1 receptor, IL‐1 receptor accessory protein, and the Fc portion of the human IgG1. Rilonacept “pocket” binds to IL‐1α and IL‐1ß acting as an IL‐1 trap blocking the interaction with their specific receptor. Fc indicates fragment crystallizable region; IL‐1RAcP, IL‐1 receptor accessory protein; IL‐1RI, IL‐1 receptor; IL, interleukin. Reprinted from Klein et al 25 with permission. ©2020, Elsevier.